What is Profhilo and how does it differ from traditional dermal fillers?

Profhilo is a hybrid hyaluronic acid biostimulator that combines high-concentration HA with amino acids to stimulate collagen and elastin production, focusing on skin quality and hydration rather than volume restoration. Unlike volumetric fillers like Juvéderm Ultra or Radiesse, Profhilo works through bio-stimulation rather than adding bulk, making it a non-volumetric alternative for skin quality treatments.

Who is distributing Profhilo in the United States?

Evolus secured exclusive U.S. distribution rights to Profhilo from IBSA under a 15-year agreement. Evolus, the maker of Jeuveau (prabotulinumtoxinA), now offers both neuromodulator and biostimulator options to practices.

How does Profhilo complement or compete with existing injectables?

Profhilo appeals to practices seeking skin-quality treatments that can complement traditional filler protocols or serve as a non-volumetric alternative. It differentiates from calcium hydroxyapatite options like Radiesse and traditional HA fillers, giving practices another tool to address hydration and collagen stimulation without volume addition.

What was the deal structure between Evolus and IBSA for Profhilo?

Evolus licensed exclusive U.S. distribution rights under a 15-year agreement with no upfront payments, meaning economics are tied to commercial success. This structure signals confidence in market uptake and aligns incentives between the licensor and distributor.

What mechanism does Profhilo use to improve skin quality?

Profhilo uses high-concentration hyaluronic acid combined with amino acids to stimulate collagen and elastin production, driving skin hydration and quality improvement. This bio-stimulation mechanism differentiates it from volumetric fillers that rely on direct tissue augmentation.

Monday, August 24, 2026 Never miss a recall or a rule change Go Pro · $20/mo →

RegulatoryAbbVie Launches Phase 2 Forehead Lines Studytoday MarketFacial Rejuvenation Market Forecast to Hit $5.66B by 20302 days ago Business & M&AAllergan Aesthetics Overhauls Loyalty Programtoday Devices & TechXERF Technology Enters Australian Market for Skin Tightening2 days ago Business & M&AEvolus Expands Estyme to Canada, Australia, New Zealandtoday MarketArm Fat Now Top Body Sculpting Concern in Singapore2 days ago Devices & TechSofwave Hits One Million Treatments Milestonetoday RegulatoryCKD Bio Pursues China Botox Approval—2027 Launch Targeted2 days ago RegulatoryRevance Wins FDA Nod for Under-Eye Injectablesyesterday MarketGLP-1 Pill Era Is Forcing Beauty Market Shiftyesterday InjectablesAEON Releases Expanded ABP-450 Botox Biosimilar Datayesterday Devices & TechUltherapy PRIME Real-Time Imaging Reshapes Midface Liftingyesterday

Injectables

Evolus Secures Exclusive U.S. Profhilo License From IBSA — Skin Quality Injectable Now in Play

Evolus expands beyond neuromodulator competition with a 15-year exclusive deal for the hydration-focused biostimulator, no upfront fees.

By Evan at Inside MedSpa · Jul 12, 2026

1-YEAR MOVE

EOLS ▼15.6% ABBV ▲11.6%

1-year price move by ticker
Ticker	Company	1-year change
EOLS	Evolus	−15.6%
ABBV	AbbVie (Allergan Aesthetics)	+11.6%

Evolus has licensed exclusive U.S. distribution rights to Profhilo from IBSA under a 15-year agreement with no upfront payments—a structure that signals confidence in market uptake and ties economics to commercial success. Profhilo is a hybrid HA biostimulator (not PLLA or CaHA) that combines high-concentration hyaluronic acid with amino acids to drive skin quality and hydration rather than volume restoration.

This move diversifies Evolus beyond Jeuveau (prabotulinumtoxinA) and positions the company to capture medspa demand for skin-quality treatments that complement or compete with traditional filler protocols. Profhilo's mechanism—collagen and elastin stimulation via HA—appeals to practices seeking non-volumetric alternatives and differentiates from Galderma's Radiesse (CaHA) or AbbVie's Juvéderm Ultra (HA filler).

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/evolus-profhilo-exclusive-us-license-ibsa/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

STRATA Skin Sciences-50%Hims & Hers Health+6.03%Estée Lauder+6.02%Bausch Health (Solta)-5.43%The Beauty Health Company (HydraFacial)+3.65%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	8
Jul '26	23	4
Aug '26	5	0

The 50-state regulation tracker →

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.

The twice-a-week intelligence brief Go Pro · $20/mo →

Evolus Secures Exclusive U.S. Profhilo License From IBSA — Skin Quality Injectable Now in Play

Share

Discussion

Leave a comment

By the time it's news, it's too late.